Executive Committee
The Board of Directors has delegated the management of the company to the CEO, who, in turn, has delegated certain powers to the members of the Executive Committee. The Organizational Regulations of the Board of Directors govern, among other matters, the delegation from the Board of Directors to the CEO and the sub delegation by the CEO. The regulations can be viewed at medmix.swiss/en/Investors/Governance (under Downloads).
Members of the Executive Committee
René Willi, Chief Executive Officer and member of the Executive Committee, is a Swiss citizen born in 1967.
Binding interests: Member of the Board of Corticalis A/S and member of the Board of Botiss Biomaterials GmbH.
Before joining medmix as CEO on June 1, 2024, René Willi was the Chief Executive Officer of the Global Oral Reconstruction Group at Henry Schein Inc. and a member of the Henry Schein Inc. Executive Management Committee, a company he joined in 2013. René Willi was previously Executive Vice President, Surgical Business Unit, at Institut Straumann AG in Basel, Switzerland, which he joined in 2005. Prior to Straumann, René held roles in the cardiovascular division of Medtronic. Before that, he served as a management consultant with McKinsey & Company. René started his career in plant engineering as a process engineer (Ems-Inventa) and senior manager sales & engineering (Von Roll Inova AG). René Willi was a member of medmix’ Board of Directors from 2022 until he joined the company as CEO.
René holds a Master’s degree in Chemical Engineering, a PhD in Technical Sciences and a postgraduate Master’s degree in Industrial Engineering and Management from the Swiss Federal Institute of Technology – ETH Zurich. He is an alumnus of the Medtronic marketing leader program of the Wharton School, University of Pennsylvania.
Jennifer Dean, Chief Financial Officer and member of the Executive Committee, is an Australian citizen born in 1968.
Binding interests: Member of the Board of the Australian-Swiss Chamber of Commerce since 2022. Member of the Board of Directors at Medartis AG since 2024.
Jennifer Dean has been the CFO of medmix since September 2021. Prior to the incorporation and separate listing of medmix Ltd, Jennifer Dean acted as the Chief Financial Officer for the Applicator Systems division of Sulzer Ltd (from 2017). She was CFO for Product Lines at GE Power Services from 2015 to 2017. Prior to this, she held a number of positions at Alstom, including Vice President Finance for the Thermal Services division (2013-2015), Finance Director for the Gas Turbine Product Line (2010-2013), and Finance Director for Environmental Control Systems & Carbon Capture Systems (2006-2010).
Jennifer Dean holds a Bachelor’s degree in Economics from Macquarie University, Sydney, Australia, and is a chartered accountant (Chartered Accountants Australia & New Zealand) and associate member of the Governance Institute of Australia.
Jasper den Ouden, Chief HR and Sustainability Officer and member of the Executive Committee, is a Dutch citizen born in 1975.
Binding interests: None.
Jasper den Ouden has served as CHRO & Sustainability Officer since March 1, 2025. Previously, he was the Chief HR Officer at SR Technics Group (2019-2025). Before that, he was the Global HR Director for Powder Coatings and Group Marketing at AkzoNobel (2017-2019). Prior to joining AkzoNobel, he served as Head of HR at Satair Group, an Airbus subsidiary (2014-2017). Jasper's earlier career includes multiple HR leadership roles at Airbus and a consulting stint in Madrid at Willis Towers Watson.
Jasper completed Doctoral Studies in Economics at the Universidad Oberta de Catalunya, Barcelona and holds an International MBA from IE School, and a Bachelor's Degree in Management, Economics & Law from Haarlem Business School. He is also an alumnus of various professional certification programs, including the Airbus Leadership University.
Xavier Schops, Chief Legal Officer, Company Secretary, Head of Corporate Affairs and member of the Executive Committee, is a French citizen born in 1968.
Binding interests: Member of the Board and Treasurer of ACC Europe – Association of Corporate Counsel.
Xavier Schops has headed the Legal and Compliance department and served as Company Secretary since August 2022. He joined the Executive Committee on November 1, 2023, since when he has also served as Head of Corporate Affairs. He joined medmix from Sonova AG (2019-2022), where he served as General Counsel, then supported Mergers & Acquisitions. Previously, he was General Counsel for Europe, Middle East and Africa at PPG Industries (2009-2016) and Vice President & Chief Counsel Europe for Mondelez International (2016-2019). Xavier Schops started his career at the Michelin Group, for which he worked in Europe and Asia.
Xavier Schops holds a post-graduate degree in Corporate Law and Tax from Paris University (Pantheon-Assas) and a Master’s degree in Corporate Finance and Accounting from Neoma Business School.
Details of former members of the Executive Committee are provided in the corporate governance sections of the full-year reports for financial year 2024 and previous financial years, available at medmix.swiss/investors/financial-reports (under Downloads).
Changes after the balance sheet date: Charity Kufaas has joined the Company as Chief Strategy and Transformation Officer and member of the Executive Committee effective January 1, 2026.
Number of permitted activities
No member of the Executive Committee may hold more than five mandates, of which no more than one may be in listed companies (see Art. 33 of the Articles of Association at medmix.swiss/en/Investors/Governance; under Downloads). Exceptions (e.g., for mandates held at the request of medmix) are also defined in Art. 33 of the Articles of Association. All members of the Executive Committee comply with these requirements, and no exceptions were granted in the reporting period.
Management contracts
There are no management contracts existing with third parties. None of the Executive Committee members have a contract with a notice period exceeding 12 months.